High-dose therapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT) is offered to patients with chronic lymphocytic leukemia (CLL) both as front-line consolidation and in the relapsed setting. The role of HDT in the front-line consolidation setting in CLL is uncertain. Literature search of PUBMED and Cochrane until 14 November 2014 and the last 2 years of abstracts from relevant conferences was undertaken. End points included benefits (overall survival; OS, PFS, event-free survival; EFS) and harms (adverse events, secondary malignancies, treatment-related mortality). The search identified 495 references of which four studies met inclusion criteria. Altogether, 301 patients were randomized to the HDT/auto-HCT arm and 299 patients to the control arm. Offering front-line HDT/auto-HCT did not result in statistically significant improvement in OS (Hazard ratio (HR) = 0.91; 95% confidence interval (CI) = 0.62, 1.33) or PFS (HR = 0.70; 95% CI = 0.32, 1.52). There was a statistically significant advantage favoring HDT/auto-HCT for EFS (HR = 0.46; 95% CI = 0.26, 0.83). Moreover, HDT/auto-HCT did not result in higher rate of secondary malignancy (risk ratio = 1.06; 95% CI = 0.55, 2.05) or treatment-related mortality (risk ratio = 1.32; 95% CI = 0.43, 4.06). Offering HDT/ auto-HCT as front-line consolidation in patients with CLL does not improve OS. At present this approach should not be offered outside the context of a clinical trial.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western hemisphere. 1 It accounts for 30% of new cases of leukemia with an annual incidence rate of 3.5-3.7 per 100 000 in the United States and United Kingdom. 2, 3 Although the median age at diagnosis is 72, over 30% of CLL patients are younger than 65 years. 4 Advances in our understanding of the biologic, molecular and genetic aspects of the disease, coupled with development of novel chemotherapies, targeted therapies, and chemoimmunotherapy combinations, have translated thus far into improved responses but cure remains elusive. [5] [6] [7] [8] [9] [10] [11] [12] Allogeneic hematopoietic cell transplantation is the only known treatment modality that can offer the possibility of cure in CLL in approximately 50% of cases. [13] [14] [15] However, the procedure has been traditionally associated with increased morbidity and mortality preceding the evolution of reduced intensity conditioning regimens.
High-dose therapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT) has been offered to patients with CLL, both as front-line consolidation and in the relapsed setting. 10, 11, 16, [17] [18] [19] [20] [21] Use of HDT/auto-HCT as a consolidative strategy following front-line therapy has been evaluated in the context of a randomized controlled trial by several investigators. Accordingly, we performed a systematic review aiming at evaluating the totality of evidence pertaining to the efficacy (or lack thereof) of this approach in newly diagnosed CLL.
MATERIALS AND METHODS

Search and study selection
A comprehensive electronic search of MEDLINE and Cochrane Library was performed from inception until 14 November 2014 using the strategies reported in Supplementary Information. 22 In addition, to identify any recently completed studies, which have not yet been published as full manuscripts, a manual search of the last 2 years of abstracts form the American Society of Hematology, American Society of Clinical Oncology, European Society for Medical Oncology, and the European Hematology Association was undertaken. All randomized controlled trials studying the use of HDT followed by auto-HCT in adult patients with CLL were included in this systematic review independently by two authors.
Data collection
All data were extracted using a standardized data extraction form independently by two authors. Once the data were entered into a data set, a random data check was performed for accuracy. All disagreements between authors were resolved by consensus with a third author. Data were collected on study and patient characteristics, treatment and benefits (overall survival; OS, PFS, event-free survival; EFS) and harms (any moderate or severe adverse events, secondary malignancies, treatment-related mortality). The methodological quality of each study was evaluated using the Cochrane risk of bias tool for randomized studies. 23 
Statistical analysis
Dichotomous data were summarized using risk ratio and pooled under random-effects model. 24 Time-to-event data were pooled and reported as hazard ratio (HR) and 95% confidence interval (CI) and pooled using generic inverse variance under the random-effects model. Heterogeneity between pooled studies was assessed using I 2 statistic and categorized as low (o 30%), moderate (30-50%) or high (450%). 25 All analyses were performed using RevMan 5.1 software. 26 This systematic review is reported according to PRISMA guidelines. 27 
RESULTS
Study selection
A total of 495 references were identified through a systematic search of PUBMED/MEDLINE and Cochrane. Four randomized controlled trials, which included a total of 600 subjects, were eligible for inclusion. 11, [19] [20] [21] Selection process of studies is reported in Figure 1 .
Patient, disease and treatment characteristics Among the four trials included in this systematic review, 301 patients were randomized to HDT followed by auto-HCT arm versus 299 patients on observation arm. Patient and treatment characteristics are reported in Table 1 .
Methodological quality
The overall methodological quality of included studies is moderate ( Table 2 ).
Overall survival All four studies (600 patients) reported data on OS. There was no statistically significant difference in OS with the use of auto-HCT versus observation (HR = 0.91 (95% CI = 0.62-1.33), P = 0.64). There was no heterogeneity between studies (I 2 = 0%) (see Figure 2a ).
PFS and EFS
The definitions of progression-free and EFS as provided in each paper are reported in the Supplementary Information. When PFS and EFS are combined in analysis, there is a statistically significant benefit with the use of auto-HCT versus observation (HR = 0.54 (95% CI = 0.35-0.82), P = 0.004). The heterogeneity between studies remains high (I 2 = 69%) (See Figure 2b ). Two studies (178 patients) reported data on PFS. There was no statistically significant difference in OS with the use of auto-HCT versus observation (HR = 0.70 (95% CI = 0.32-1.52), P = 0.37). Newly diagnosed or first relapse B CLL
Abbreviations: APO = Adriamycin, prednisone, VCR; ASCT = autologous hematopoietic cell transplant; BEAM = BCNU, etoposide, cytarabine, melphalan; CR = complete response; CTX = chemotherapy; CY = cyclophosphamide; DHAP = dexamethasone, high-dose cytarabine, cisplatinum; FC = fludarabine plus cyclophosphamide; FM = fludarabine and melphalan; HD = high-dose; nPR = nodular partial response; PBSC = peripheral blood stem cells; R = rituximab; VGPR = very good partial response.
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However, there was high heterogeneity between studies (I 2 = 71%). Two studies (422 patients) reported EFS. A statistically significant benefit was observed with the use of auto-HCT versus observation (HR = 0.46 (95% CI = 0.26-0.83), P = 0.01). The heterogeneity between studies was high (I 2 = 75%)
Adverse events
The most commonly reported grade 3 and 4 adverse events were viral and/or other infectious diseases and secondary malignancies. Incidence of infectious disease was reported by three studies (358 patients). There was no significant difference with the use of auto-HCT versus observation for the incidence of infection. All four studies (581 patients) reported incidence of secondary malignancies. There was no statistically significant difference with the use of auto-HCT versus observation (HR = 1.06 (95% CI = 0.55-2.05), P = 0.86). There was no heterogeneity between studies (I 2 = 0%) (see Figure 3a) . Looking only at incidence of AML or myelodysplastic syndrome (MDS), all four studies (581 patients) reported data. There was no statistically significant difference with the use of auto-HCT versus observation (HR = 1.95 (95% CI = 0.60-6.34), P = 0.27). There was no heterogeneity between studies (I 2 = 0%) (see Figure 3b ). Treatment-related mortality Two studies (276 patients) reported data for treatment-related mortality. There was no statistically significant difference with the use of auto-HCT versus observation (HR = 1.32 (95% CI = 0.43-1.06), P = 0.63). There was no heterogeneity between studies (I 2 = 0%) (see Figure 3c ).
DISCUSSION
Findings of this meta-analysis do not support the use of HDT/auto-HCT as a consolidative strategy following front-line therapy in patients with CLL, as this strategy was not associated with improvement in PFS or OS. This is in line with conclusions drawn by prior investigators. 28, 29 Morever, large registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR) showed no auto-HCT activity for year 2011. 30 Whether the results indicate an absence of evidence or evidence of absence cannot be determined as the results in most cases were associated with wide CIs. Analysis of included manuscripts show that enrollment to these trials was relatively challenging as reflected by the long time needed to enroll the required number of subjects. For example, Sutton et al. randomized 96 subjects over a period of 4.7 years despite participation of many transplant centers in Italy; and Michallet et al. 11 completed accrual of 223 subjects in~6 years despite participation from transplant centers from 11 countries in Europe. Another major limitation when evaluating these studies is the fact that subjects were treated with therapies, which are considered suboptimal by present standards. For instance Sutton et al. offered an induction regimen consisting of three monthly cycles of mini-CHOP (doxorubicin 25 mg/m 2 and VCR 1 mg/m 2 intravenously on day 1 and cyclophosphamide 300 mg/ m 2 per day and prednisone 40 mg/m 2 per day given orally on days 1-5. Fludarabine was given at IV 25 mg/m 2 per day intravenously or 40 mg/m 2 per day orally on days 1-5 as monotherapy for three cycles after third cycle mini-CHOP was completed. 21 This study did not include rituximab, which has been shown to improve survival when combined with fludarabine and cyclophosphamide in the front-line setting. 8, 21 The authors mentioned that consolidation with HDT/auto-HCT, vis-à-vis observation, improved duration of response in patients who achieved first CR. 21 This benefit is possibly explained by the fact that mini-CHOP and, subsequently, fludarabine monotherapy, as prescribed, were suboptimal therapies in CLL, hence patients randomized to the observation arm were at an inherent disadvantage when compared with those who received HDT/auto-HCT and benefited from the consolidation. 21 This argument is supported by findings from Magni et al. 20 who showed that HDT/auto-HCT failed to show improvement in responses, PFS and OS when compared with a contemporary chemoimmunotherapy regimen, consisting of fludarabine, cyclophosphamide and rituximab. Interestingly, the European intergroup randomized trial comparing autografting with observation demonstrated a benefit in lowering risk of relapse as well as improved EFS in the HDT/auto-HCT arm despite the fact that 73% of the subjects in the transplant arm did not receive rituximab as part of the initial regimen.
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When assessing harms, we noted that HDT/auto-HCT was not associated with a higher risk of secondary (any) malignancies (Figure 3a) . A twofold higher incidence of secondary AML/MDS, albeit not statistically significant, was observed following HDT/ auto-HCT (Figure 3b) . Sutton et al. 21 reported a 4.2% incidence of AML/MDS in the setting of HDT/auto-HCT at a median follow-up of 50 months. Brion et al. 19 reported two deaths attributed to secondary AML in 39 subjects who were treated with HDT-auto-HCT. None of the subjects who received HDT/auto-HCT in the study by Magni et al. 20 were reported to have developed AML/ MDS; it is possible this could be explained by a relatively short follow-up. The relatively low incidence of secondary AML/MDS from these studies 19-21 compared with 9-12% incidence reported in a previous systematic review by our group 10 is probably explained by the fact that the latter patients were offered HDT/ auto-HCT in the relapsed disease setting, suggesting an increased risk of leukemogenesis as a result of cumulative exposure to multiple lines of chemotherapy in this pre-treated group in addition to using TBI as part of the preparative regimen; and/or perhaps by a smaller rate of events in the present analysis (eight AML/MDS cases in 274 autografted patients), possibly related to a relatively short follow-up as previously stated. Although it was not the main scope of this analysis, we were not able to perform a subgroup analysis to identify differences in second cancers in patients who received TBI-based conditioning regimens versus chemotherapy-based ones due to the absence of data to perform such comparison. Emergence of potent novel therapies for patients with CLL, namely ibrutinib and idelalisib, among others, 6, 31, 32 have demonstrated impressive responses in the setting of relapsed/refractory CLL even in subjects with high-risk genomic aberrations; and it is likely that these agents would eventually move to the front-line treatment in the future. These drugs, together with availability of reduced allogeneic HCT, which has reduced the morbidity and mortality of this procedure, have definitely redefined the therapeutic landscape of CLL.
Given the wide CIs associated with effect size for all outcomes confirming the inconclusive nature of results, findings of this meta-analysis do not support offering HDT/auto-HCT in its current form as a consolidative approach after front-line therapy in patients with CLL outside the context of a clinical trial. Figure 3 . Forest plot for (a) incidence of secondary malignancies; (b) incidence of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); and (c) incidence of treatment-related mortality. The summary estimate (risk ratio) from individual studies is indicated by rectangles with lines representing the 95% confidence intervals (CIs). The summary pooled estimate from all studies is represented by the diamond, and the stretch of the diamond indicates the corresponding 95% CI.
